There is now general consensus that pancreatic cancer is a systemic disease at the time of diagnosis, even among patients with apparent localized disease. 1 This clinical observation was in fact appreciated many decades ago, when it became apparent that the vast majority of patients operated upon with curative intent experienced metachronous recurrence even when the operation went ''perfectly.'' However, despite improved clarity around the natural history of pancreatic adenocarcinoma, there remains debate on optimal treatment sequencing. The manuscript by Altman and colleagues in this issue of Annals of Surgical Oncology adds to the now robust body of literature demonstrating that patients who undergo surgery (first) for operable pancreatic cancer may never receive intended adjuvant therapy. 2 If this is true, what is preventing the more widespread use of systemic therapy first for this disease?
IS THERE ANYTHING TO BE LEARNED FROM HISTORY?
Because the operation of pancreaticoduodenectomy (Whipple procedure) was (and remains) of significant magnitude and because many patients who successfully underwent this operation recurred even within 1 year of surgery, treatment sequencing other than immediate surgery was an obvious oncologic alternative. 3 Initial clinical trials of neoadjuvant therapy were developed in an effort to both: identify those patients with rapidly progressive disease at the time of posttreatment re-staging evaluation (prior to surgery) and thereby avoid such a large operation which would be of no oncologic benefit; and, to better define (select) those patients who may live long enough to benefit from a large operation as they were felt to be the ones most likely to have stable or responding disease after the receipt of systemic therapy, chemoradiation, or both. [3] [4] [5] [6] [7] [8] However, there was considerable criticism of treatment sequencing other than a surgery-first approach, especially from those institutions involved in the study of adjuvant therapy. It is true that neoadjuvant treatment sequencing was developed before we had systemic therapies as effective as exist today but, investigators pursued this approach in an effort to better select patients to go and NOT to go to the operating room as well as to develop the infrastructure needed to deliver systemic therapy and chemoradiation to patients of advanced age who often had biliary obstruction. In fact, the lack of such infrastructure, resulting in the inability to consistently deliver neoadjuvant therapy to newly diagnosed patients with localized pancreatic cancer, may represent the major obstacle to neoadjuvant treatment sequencing. 9 As therapies improved, the survival duration of operated patients became much longer, eventually generating a greater level of enthusiasm for a trip to the infusion center rather than the operating room as initial treatment of localized, operable pancreatic cancer. [10] [11] [12] It is important to remember that the initial attempts at neoadjuvant treatment sequencing were developed in an effort to advocate for those patients who were at highest risk for early postoperative failure (by detecting disease progression at the time of preoperative re-staging and avoiding surgery); an argument which proved to be largely unsuccessful in swaying opinion against immediate surgery. Enthusiasm for neoadjuvant therapy did not gain momentum until the survival durations of those patients who successfully completed all neoadjuvant therapy and surgery began to increase-consistent with the incorporation of more effective systemic therapy and chemoradiation. [10] [11] [12] However, those institutions which have not solved the challenges of patient management (biliary decompression [routine use of metal stents], supportive care, diabetes management, hydration, etc.) have struggled to adapt to anything other than a surgery-first approach.
IN A FIELD WHERE INTENT TO TREAT IS SO HIGHLY VALUED, WHY IS DARWINIAN SELECTION SO ADMIRED?
The manuscript by Altman and colleagues in this issue of Annals of Surgical Oncology highlights the fact that only a minority of patients who undergo successful surgery for localized pancreatic cancer receive intended adjuvant therapy this was true even for the time period of 2009-2014 by which time multimodality therapy was well accepted for this disease. The obvious concern is that as systemic therapies become even more effective, they will never reach the patient if a surgery-first approach is taken. Despite advances in surgery and perioperative management, challenges with postoperative recovery, due to the magnitude of the operation which often is performed in patients of advanced age, may be hard to overcome. As discussed in the Altman manuscript, perioperative results may be improved by the concentration of pancreatic surgery in higher-volume centers; however, there is increasing pressure placed on employed physicians to keep patients within their health system/network regardless of diseasesite expertise. 13 Importantly, a neoadjuvant approach includes all patients at the time of diagnosis-assuming they have a performance status acceptable for anticancer therapy (as opposed to best supportive care) and a CT/MRI which reveals a resectable or borderline resectable primary pancreatic cancer. This reflects the real-world experience in managing patients who often demonstrate a wide spectrum of comorbidities and family support and usually require durable biliary decompression. In sharp contrast is the case with clinical trials of adjuvant therapy which include only patients who: are found not to have metastatic disease at the time of planned pancreatectomy (80-90% of the total if preoperative imaging is well done); survive surgery and recover in a timely fashion and are agreeable to further treatment; have no evidence of early disease progression on postsurgical re-staging evaluation; and pass the assessment of the medical oncologist-which is becoming more difficult as adjuvant therapy with FOLFIRINOX may have raised the bar of patient performance status due to the anticipated toxicities of therapy. Indeed, the results of the recently reported Unicancer-GI-PRODIGE trial of adjuvant modified FOLFIRINOX (mFOLFIRINOX) versus gemcitabine reflect a Darwinian selection bias that may make the study results impossible to adapt to the clinical practice of the average oncologist. 14 The results of this trial likely apply only to the fittest XX% (could be X% if one considers only the Medicare population in the SEER registry?) of all patients who are brought to the operating room for planned surgical resection of their pancreatic cancer immediately after diagnosis-the true denominator if an intent-to-treat analysis were performed. Pancreatic cancer may be somewhat unique within solid tumor oncology in the complexity of the operative gastrointestinal reconstruction which predisposes to a more prolonged recovery especially in patients of advanced age with some degree of medical comorbidity.
Undoubtedly there are some patients with operable pancreatic cancer who likely cannot tolerate multiple treatments in series, although they may be hard to identify as distinct from others at the time of diagnosis. For this subset of patients, is surgery better than no surgery at all, which could happen if the toxicities of neoadjuvant therapy make surgery no longer an option? Available evidence would suggest not. 1, 2, 15 Surgery, as a ''Hail Mary pass'' for this disease, almost never works. Darwinian selection should be used in the treatment sequencing of operable pancreatic cancer; it should be used to help determine which patients are most likely to benefit from surgery (while maintaining careful record of all patients who initiated treatment with curative intent)-NOT after the operation has been done in an effort to determine which patients will benefit from adjuvant therapy. Chemotherapy and radiation can both be turned off if the treatment appears to be worse than the disease for a given patient. We do not have the ability to do this with surgery; once the decision has been made, anesthesia induced and the operation completed, the mortality/morbidity of pancreatic surgery has been conveyed to the patient in its entirety. Reports of surgery-first or surgery-last which fail to report the denominator of all patients (recorded at the time of diagnosis after high-quality cross-sectional imaging [staging]) by intention to treat contain an inherent selection bias which renders such data uninterpretable to a more generalized population. 14, 16 WHAT SHOULD WE DO?
Patients with newly diagnosed pancreatic cancer should be accurately staged. An objective CT-based system for radiographic staging allows one to apply stage specific therapy to all patients who have a performance status and medical condition acceptable for anticancer therapy (Table 1) . Durable biliary decompression is combined with optimal blood sugar control, diet and nutritional counseling and psychological support within the framework of a multidisciplinary program. If available, genetic counseling is also included and when not available, genetic testing can still be performed if the patient is willing to pay for this service. Hopefully this all leads to enrollment in a clinical trial. When a clinical trial is not available, we would recommend neoadjuvant therapy for all stages of non-metastatic pancreatic cancer. With the use of accurate staging, we can provide the patient and his/her family the likelihood of completing all intended neoadjuvant therapy and surgery ( Table 2) . For patients who are unable to travel, have limited social and family support, or have medical comorbidities that make multiple treatments in series likely impossible, goals of therapy need to be redefined. Not everyone is a candidate for 4 months of chemotherapy, radiation/chemoradiation and surgery. For those who begin neoadjuvant therapy (mFOLFIRINOX and gemcitabine doublets/triplets are becoming the standard outside of a clinical trial), re-staging should be performed after 2 months of therapy and in general, they are treated as outlined in Table 3 and Fig. 1 . The delivery of potentially curative neoadjuvant therapy requires, at a minimum: dedicated medical, radiation and surgical oncologists, talented radiologists, experienced interventional gastroenterologists and cytopathologists, and a team of support personnel (advanced practice providers, dieticians, diabetes specialists and psychologists). Herein lies the Table 3 illustrating treatment guidelines for the management of nonmetastatic Pancreatic Cancer outside of a Clinical Trial-as in Table 3 , we assume that those with distant disease progression receive second line therapy or an appropriate clinical trial challenge and probably the reason for the lack of more widespread application of neoadjuvant therapy to a disease where it seems to make so much sense. Surgery first is an easier paradigm to complete for the medical team as no one is responsible for those patients who drop out along the way. Importantly, the survival results of those who pass the test of Darwinian selection and successfully receive adjuvant therapy cannot be extrapolated to the patient at the time of diagnosis; no one really knows if they will ever receive adjuvant therapy. The data contained in the Altman manuscript suggests that their chances are very low. The use of surgery-first for operable pancreatic cancer appears to be a dead-end street at least for those aged 66 or older who are in the SEER database. The failure of treatment guidelines to recognize this (in resectable disease) reflects the challenge of achieving consensus among experts who may not realize that the inability to deliver adjuvant therapy is stage agnostic-and more dependent on the operation performed and the age and medical condition of the patient. Risking the ability to deliver systemic therapy to patients with resectable pancreatic cancer, by embarking on a surgeryfirst approach, may negatively impact the survival of those patients most likely to benefit from multimodality therapy.
